Synapse - Genitourinary Oncology Service

Results (5695)

Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Motzer, R. J.; Escudier, B.; Bukowski, R.; Rini, B. I.; Hutson, T. E.; Barrios, C. H.; Lin, X.; Fly, K.; Matczak, E.; Gore, M. E.
BJU International (2012)

Fulltext@MSK | Save

A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Hutson, T. E.; Bukowski, R.; Rini, B. I.; Gore, M. E.; Larkin, J. M.; Figlin, R. A.; Barrios, C. H.; Escudier, B.; Lin, X.; Fly, K.; more...
BJU International (2012)

Fulltext@MSK | Save

Subgroup analysis of the phase 3 RECORD-1 trial of everolimus in patients with metastatic renal cell carcinoma: 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies

Meeting Abstract

Figlin, R. A.; Motzer, R.; Hutson, T. E.; Oudard, S.; Porta, C.; Grünwald, V.; Ravaud, A.; Panneerselvam, A.; Calvo, E.
BJU International (2012)

Fulltext@MSK | Save

Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Escudier, B.; Rini, B. I.; Hutson, T. E.; Gore, M.; Oudard, S.; Tarazi, J.; Rosbrook, B.; Williams, J. A.; Kim, S.; Motzer, R. J.
European Urology, Supplements (2012)

Fulltext@MSK | Save

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer

Journal Article

Saltz, L.; Badarinath, S.; Dakhil, S.; Bienvenu, B.; Harker, W. G.; Birchfield, G.; Tokaz, L. K.; Barrera, D.; Conkling, P. R.; O'Rourke, M. A.; more...
Clinical Colorectal Cancer (2012)

Fulltext@MSK | Save

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α